SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-051301
Filing Date
2020-11-05
Accepted
2020-11-05 16:07:06
Documents
59
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-10q_20200930.htm   iXBRL 10-Q 2630739
2 EX-31.1 fate-ex311_6.htm EX-31.1 9781
3 EX-31.2 fate-ex312_85.htm EX-31.2 9922
4 EX-32.1 fate-ex321_9.htm EX-32.1 6719
  Complete submission text file 0001564590-20-051301.txt   11156770

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fate-20200930.xsd EX-101.SCH 59159
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fate-20200930_cal.xml EX-101.CAL 50478
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20200930_def.xml EX-101.DEF 220571
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20200930_lab.xml EX-101.LAB 475981
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20200930_pre.xml EX-101.PRE 358849
10 EXTRACTED XBRL INSTANCE DOCUMENT fate-10q_20200930_htm.xml XML 2793095
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 201290447
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences